Alnylam Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

ALNY

Classement en actions #793
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily... Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
Prix de l'action
$226.16
Capitalisation boursière
$30.26B
Changement (1 jour)
-1.97%
Changement (1 an)
-52.29%
Pays
US
Échange Alnylam Pharmaceuticals, Inc. (ALNY)

Catégorie

Healthcare
Historique des divisions d’actions pour Alnylam Pharmaceuticals, Inc. (ALNY)
L’action Alnylam Pharmaceuticals, Inc. (symbole : ALNY) a subi un total de 0 divisions.
La division la plus récente a eu lieu le Oct 21, 2026.
Une action ALNY achetée avant le Oct 21, 2026 équivaudrait aujourd’hui à 0 actions ALNY.
Liste des divisions d’actions
Année Division Multiplicateur Multiplicateur cumulatif
Pas assez de données pour les dates fournies.
Divisions d’actions d’entreprises similaires ou concurrentes
Entreprise Nombre de divisions d’actions Multiplicateur cumulatif Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH